TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02661750

Intervention type: DRUG
Intervention: Bowel Preparation
Description: Standard 1/2 Dose: 153 g MiraLAX + 32 oz Gatorade 2 liters, 2 liters NuLYTELY, 1 liter MoviPrep, 16 oz (1 bottle) SuPREP, 10 oz (1 bottle) MagCitrate.~Standard Full Dose: 306 g MiraLAX + 64 oz Gatorade, 4 liters NuLYTELY, 2 liters MoviPrep, 32 oz (2 bottles) SuPREP, 20 oz (2 bottles) MagCitrate.~Step 1: 51 g MiraLAX\* noon the day-prior; Full dose - 51 g MiraLAX 6 PM day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 2: 1/2 dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 3: Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 4: 1/2 dose 6 PM 2 days-prior; Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 5: Full dose 6 PM 2 days-prior; Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.

Intervention type: DRUG
Intervention: Bowel Preparation
Description: Standard 1/2 Dose: 153 g MiraLAX + 32 oz Gatorade 2 liters, 2 liters NuLYTELY, 1 liter MoviPrep, 16 oz (1 bottle) SuPREP, 10 oz (1 bottle) MagCitrate.~Standard Full Dose: 306 g MiraLAX + 64 oz Gatorade, 4 liters NuLYTELY, 2 liters MoviPrep, 32 oz (2 bottles) SuPREP, 20 oz (2 bottles) MagCitrate.~Step 1: 51 g MiraLAX\* noon the day-prior; Full dose - 51 g MiraLAX 6 PM day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 2: 1/2 dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 3: Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 4: 1/2 dose 6 PM 2 days-prior; Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 5: Full dose 6 PM 2 days-prior; Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.
Study: NCT01123096

Intervention type: PROCEDURE
Intervention: Cough Stress Test
Description: A cough stress test is performed by using a catheter to introduce 300ml of sterile water into the bladder. The patient is then asked to stand and cough forcefully and the clinician will observe for urine loss.

Intervention type: OTHER
Intervention: 24 Hour Pad Test
Description: The patient will be provided with a standard number of pads in a sealed bag that have been pre-weighed. The patient will wear the pads for 24 consecutive hours then return the all the pads within the bag for weighing post usage.
Study: NCT03815968

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low sodium diet
Description: included in the diet mostly low sodium food. avoid tinned or smoked, food. avoid adding salt to the food.
Study: NCT01017419

Intervention type: BEHAVIORAL
Intervention: Counseling
Description: Informational Counseling provided after hearing aid fitting
Study: NCT02784678

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: closed reduction group
Description: Patients in the experimental group will undergo C-arm fluoroscopy-assisted minimally invasive closed reduction and internal fixation with fully threaded headless cannulated compression screws. In the experimental group, fractures will be reduced and internally fixed with fully threaded headless cannulated compression screws of appropriate lengths (Acutrak plus; Acumed Inc., Beaverton, OR, USA) under C-arm fluoroscopic guidance to restore the radial inclination and ulnar deviation of the distal radius.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: open reduction group
Description: Patients in the control group will undergo open reduction and internal fixation with a titanium plate (Ningbo Cibei Medical Treatment Appliance Co., Ltd., Ningbo, China).
Study: NCT01026259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warming of surgical incision
Description: A warming pack (chemical activation) is applied to the dressing over the surgical incision, warming to 38 degrees C, for a period of 90 minutes times 6 treatments. The first treatment occurs in the PACU.
Study: NCT00764959

Intervention type: DEVICE
Intervention: Encore Linear™ Hip System
Description: Subjects with degenerative joint disease (DJD), osteoarthritis or rheumatoid arthritis, have received the hip system and are willing to participate in the study.
Study: NCT01026259

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Warming dressing without actual warming
Description: The same type of surgical incision dressing is used but no warming treatments are administered.
Study: NCT02489591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oral appliance
Description: Patients will bring their prescribed oral appliance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BluePro oral appliance
Description: Patients without a prescribed oral appliance will have a device provided for the duration of the study (BluePro, BlueSom; used for investigational purposes only). The device provided is a prefabricated thermoplastic customizable mandibular advancement splint.
Study: NCT02331693

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-EGFR CAR T
Study: NCT03897478

Intervention type: DIAGNOSTIC_TEST
Intervention: ISCDX blood test
Description: The ISCDX test is based on gene expression changes that occur as a result of the ischemic stroke. When the stroke occurs, the immune system in the body reacts and causes changes in gene expression in several types of cells, including white blood cells, related to activation of innate and adaptive immune systems.~The ISCDX test distinguishes between cardioembolic and large artery atherosclerotic origin of stroke using a gene signature. The pattern or signature of up or down regulation for all genes for a patient determines whether the patient's pattern of gene expression is more like the pattern seen in other cardioembolic patients or more like the pattern seen in patients with large artery atherosclerotic cause of stroke.
Study: NCT02661750

Intervention type: DRUG
Intervention: Bowel Preparation
Description: Standard 1/2 Dose: 153 g MiraLAX + 32 oz Gatorade 2 liters, 2 liters NuLYTELY, 1 liter MoviPrep, 16 oz (1 bottle) SuPREP, 10 oz (1 bottle) MagCitrate.~Standard Full Dose: 306 g MiraLAX + 64 oz Gatorade, 4 liters NuLYTELY, 2 liters MoviPrep, 32 oz (2 bottles) SuPREP, 20 oz (2 bottles) MagCitrate.~Step 1: 51 g MiraLAX\* noon the day-prior; Full dose - 51 g MiraLAX 6 PM day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 2: 1/2 dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 3: Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 4: 1/2 dose 6 PM 2 days-prior; Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 5: Full dose 6 PM 2 days-prior; Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.

Intervention type: DRUG
Intervention: Bowel Preparation
Description: Standard 1/2 Dose: 153 g MiraLAX + 32 oz Gatorade 2 liters, 2 liters NuLYTELY, 1 liter MoviPrep, 16 oz (1 bottle) SuPREP, 10 oz (1 bottle) MagCitrate.~Standard Full Dose: 306 g MiraLAX + 64 oz Gatorade, 4 liters NuLYTELY, 2 liters MoviPrep, 32 oz (2 bottles) SuPREP, 20 oz (2 bottles) MagCitrate.~Step 1: 51 g MiraLAX\* noon the day-prior; Full dose - 51 g MiraLAX 6 PM day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 2: 1/2 dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 3: Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 4: 1/2 dose 6 PM 2 days-prior; Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 5: Full dose 6 PM 2 days-prior; Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.

Intervention type: DRUG
Intervention: Bowel Preparation
Description: Standard 1/2 Dose: 153 g MiraLAX + 32 oz Gatorade 2 liters, 2 liters NuLYTELY, 1 liter MoviPrep, 16 oz (1 bottle) SuPREP, 10 oz (1 bottle) MagCitrate.~Standard Full Dose: 306 g MiraLAX + 64 oz Gatorade, 4 liters NuLYTELY, 2 liters MoviPrep, 32 oz (2 bottles) SuPREP, 20 oz (2 bottles) MagCitrate.~Step 1: 51 g MiraLAX\* noon the day-prior; Full dose - 51 g MiraLAX 6 PM day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 2: 1/2 dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 3: Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 4: 1/2 dose 6 PM 2 days-prior; Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 5: Full dose 6 PM 2 days-prior; Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.
Study: NCT02007941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501
Description: From day 1 to day 3, Once(Day1) CKD-501 0.5mg is administered .
Study: NCT03864978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04067674

Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: Blood sampling for biomarker measurement
Study: NCT02933606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNC210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNC210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNC210

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01674114

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control
Study: NCT03254875

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individually tailored nurse navigation
Description: The intervention consists of systematic report of symptoms to the nurse and up to six individual, manual-based, face-to-face or telephone nurse navigator sessions depending on individual needs.
Study: NCT02027207

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shanchol
Description: We will use the killed whole cell oral cholera vaccine, Shanchol that will be manufactured by Shantha Biotechnics, in Hyderabad, India for the study. The vaccine is registered in India and is prequalified by the WHO. Shanchol is available in a single dose vial. Vaccine will be maintained at 2-8oC. Each participant over the age of one year and non pregnant females living in communities will be individually randomized to receive vaccine.Pregnancy status will be enquired verbally for all married women of child bearing age during the census update as well as before vaccination to exclude them from the study.~Prior to vaccination, informed consent will be taken from the adults and guardians of minor participants .Each dose of vaccine will be 1.5 ml in volume.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be transported from the manufacturer and will be maintained at 2-8oC. Each participant over the age of one year and non pregnant females living in communities will be individually randomized to receive placebo.Each dose of placebo will be 1.5 ml in volume.Placebo will be dispensed in liquid form in identical vials.
Study: NCT03241875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 75mg
Description: In this group, premedication is performed with 2 capsules of pregabalin 2 hours before anesthetic induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 300mg
Description: In this group, premedication is performed with 2 capsules of gabapentin 2 hours before anesthetic induction.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: In this group, no premedication is performed, but patients receive 2 capsules of placebo 2 hours before anesthetic induction.
Study: NCT01446315

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of Asthma APGAR system and tools
Description: Practices will use the Asthma APGAR control questionnaire and the care algorithm.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Asthma APGAR tools
Description: Usual care
Study: NCT01853423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamune
Description: Small amount of 0.1% rapamune ointment applied topically to affected facial areas twice daily for the first two weeks, then once daily.
Study: NCT04430660

Intervention type: OTHER
Group type: OTHER
Intervention: 13C-MRS procedure/Acetate infusion
Description: Glial metabolism will be measured via MRS utilizing a simultaneous intravenous infusion of 13C labeled acetate. An intravenous catheter will be placed in a vein of each arm, one to infuse 13C-acetate and the other to draw blood samples.
Study: NCT00124228

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Albumin
Description: albumin 1.5g/kg body weight the first day of inclusion plus 1g/kg/body weight the 3th day of inclusion.
Study: NCT04094129

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wismemo
Description: Multi-strain probiotic supplement includes Lactobacillus reuteri GMNL-89, Lactobacillus paracasei GMNL-133 and Lactobacillus plantarum GMNL-141.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT04430660

Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous glucose monitoring
Description: Participants will wear blinded continuous glucose monitoring devices (dexcom, G6) for approximately 4 weeks. Sensors will be replaced every 7-10 days.
Study: NCT04629612

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional anesthesia
Description: Regional anesthesia such as paravertebral block, pectoral block, superficial cervical plexus block, etc applies according to institution protocol
Study: NCT01623531

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fibrinogen
Description: Intravenous concentrated fibrinogen will be infused according to a hemostatic algorithm based on ROTEM (FIBTEM)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fibrinogen
Description: Intravenous concentrated fibrinogen will be infused according to a hemostatic algorithm based on ROTEM (FIBTEM)
Study: NCT02947516

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided liver biopsy
Description: Participants will undergo endoscopic ultrasound per standard technique, with liver biopsy performed at that time.
Study: NCT03618849

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Real and sham tDCS/Mozart piano sonata (K.448)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Real and sham tDCS/Mozart piano sonata (K.448)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Real and sham tDCS/Mozart piano sonata (K.448)
Study: NCT00932022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trospium Chloride, Extended Release (XR)
Description: Trospium chloride extended release 60 mg capsule taken orally once daily for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo capsule taken orally once daily for either 2 weeks or 14 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo capsule taken orally once daily for either 2 weeks or 14 weeks.
Study: NCT01125319

Intervention type: OTHER
Group type: OTHER
Intervention: blood sample

Intervention type: OTHER
Group type: OTHER
Intervention: blood sample

Intervention type: OTHER
Group type: OTHER
Intervention: blood sample
Study: NCT03353116

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the mandible first
Description: the mandible osteotomy is going to be done and fixed first

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the maxilla first
Description: the maxilla osteotomy is going to be done and fixed first
Study: NCT00644709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin tablets at starting doses of 10, 20, 40, or 80 mg once daily. Three dose adjustments were allowed at baseline, Week 17, and Week 34. Patients who did not meet the LDL-C target at any of these time points had their doses doubled except for those who were on the 80 mg dose. Treatment was given for 52 weeks.
Study: NCT00732953

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Genous stent implantation with paclitaxel-eluting balloon dilation
Description: Genous stent implantation with paclitaxel-eluting balloon therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Genous stent implantation
Description: Genous stent implantation
Study: NCT04531137

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CLA-fortified milk powder
Description: 3.4 gram of CLA-fortified milk powder one a day for 12 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo milk powder one a day for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition Counseling
Description: Individualized nutrition counseling using nutrition module at week 0, 4, and 8 for 30-45 minutes each session

Intervention type: OTHER
Group type: OTHER
Intervention: Nutrition Counseling
Description: Individualized nutrition counseling using nutrition module at week 0, 4, and 8 for 30-45 minutes each session
Study: NCT02631343

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KMC
Description: Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers

Intervention type: OTHER
Group type: OTHER
Intervention: Essential newborn care
Study: NCT03718741

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy +/- CT
Description: Adiuvant Radiotherapy +/- weekly cisplatin
Study: NCT04954378

Intervention type: DIAGNOSTIC_TEST
Intervention: radiomics
Study: NCT01610609

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Population Health Management Intervention
Description: This intervention includes:~* Care manager led patient education to promote increased patient awareness of personal cardiovascular disease (CVD) risk and~* Care manager led patient outreach to facilitate the treatment of eligible and appropriate patients with statins for primary CVD prevention
Study: NCT02007941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501
Description: From day 1 to day 3, Once(Day1) CKD-501 0.5mg is administered .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CKD-501
Description: From day 1 to day 3, Once(Day1) CKD-501 0.5mg is administered .
Study: NCT03522402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: 38 patients American Society of Anesthesiologists (ASA) class I or II aged 2-8 years undergoing tonsillectomy surgery were randomized to either the patient's head in the neutral position or 30 degree rotated lateral position. The end-tidal (ET) sevoflurane concentration used for each patient was determined using the Dixon's up-and-down method. The ratio of the end-tidal to predetermined end-tidal concentrations was maintained at 0.95-1.0 for at least 10 minutes to establish equilibration before device insertion was attempted. The first patient received a 5.0% sevoflurane concentration and the step size of increase/decrease was 0.5%.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: 38 patients American Society of Anesthesiologists (ASA) class I or II aged 2-8 years undergoing tonsillectomy surgery were randomized to either the patient's head in the neutral position or 30 degree rotated lateral position. The end-tidal (ET) sevoflurane concentration used for each patient was determined using the Dixon's up-and-down method. The ratio of the end-tidal to predetermined end-tidal concentrations was maintained at 0.95-1.0 for at least 10 minutes to establish equilibration before device insertion was attempted. The first patient received a 5.0% sevoflurane concentration and the step size of increase/decrease was 0.5%.
Study: NCT02631343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Essential newborn care
Study: NCT01418391

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus Abdominis Plane block
Description: TAP BLOCK:~dosage form: 0.5% bupivacaine 75mg with 2% xylocaine 300 mg mixed dosage: total 30 ml frequency: single shot duration: 12\~18 hours upon to the regional anesthetics choose
Study: NCT01080872

Intervention type: DEVICE
Intervention: CFR
Description: CFR will be assessed using transthoracic echocardiography with adenosine infusion.

Intervention type: DEVICE
Intervention: CFR
Description: CFR will be assessed using transthoracic echocardiography with adenosine infusion.
Study: NCT05056051

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WATS-3D tissue sampling prior to forceps biopsies
Description: WATS-3D is a brush-based tissue sampling technique. Abrasive brush sampling of large areas of the esophagus pick up cells to obtain trans-epithelial specimens. This technique samples much larger tissue areas than standard forceps biopsies. Analysis is then done by proprietary neural-network based computer scanning and molecular diagnostics to identify abnormal cells.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WATS-3D tissue sampling following forceps biopsies
Description: WATS-3D is a brush-based tissue sampling technique. Abrasive brush sampling of large areas of the esophagus pick up cells to obtain trans-epithelial specimens. This technique samples much larger tissue areas than standard forceps biopsies. Analysis is then done by proprietary neural-network based computer scanning and molecular diagnostics to identify abnormal cells. This will be done after forceps biopsies in this arm.
Study: NCT01587755

Intervention type: OTHER
Group type: OTHER
Intervention: TTOP
Description: Patient is taken care of in an intensified, optimised manner

Intervention type: OTHER
Group type: OTHER
Intervention: non-TTOP
Description: Standard medical care
Study: NCT02886754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proficiency-based progression
Description: Use of validated metrics and performance benchmarks to simulation training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: National e-learning programme only
Description: National e-learning programme (COMPASS)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: National e-learning programme only
Description: National e-learning programme (COMPASS)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: National e-learning programme only
Description: National e-learning programme (COMPASS)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard simulation
Description: Paper based simulation cases
Study: NCT04164680

Intervention type: DIAGNOSTIC_TEST
Intervention: Multimodal Neuroimaging
Description: fludeoxyglucose (FDG-)PET/MR imaging
Study: NCT04276402

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irradiation of implants with 808nm laser
Description: Irradiation of implants with 808nm laser